We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA's MAb Guidance Details Platform Manufacturing Validation; Testing Specs
EMEA's MAb Guidance Details Platform Manufacturing Validation; Testing Specs
July 2, 2007
The European Medicines Agency’s (EMEA) new draft guideline on the production and quality control of monoclonal antibodies (MAb) says it is acceptable for firms to employ a “platform manufacturing” approach for production process development.